Aeglea BioTherapeutics Announces Name Change To Spyre Therapeutics, Appoints CEO And Additional Directors, And Expands Leadership Team To Develop Next-Generation Therapeutic Combinations For The Treatment Of IBD
Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside